Focus research 2022 MELASPHINX team
Focus research 2022 MELASPHINX team Discovery of new biomarkers of resistance to melanoma immunotherapies The team showed that neutralization of TNFα, a major inflammatory cytokine, potentiates the response to anti-PD-1 in murine models of melanoma. This work...
Towards a new approach to immunotherapy in the treatment of skin cancers
Towards a new approach to immunotherapy in the treatment of skin cancer – the ARC Foundation provides long-term support Over the past 10 years, immunotherapy has significantly improved the management of patients with metastatic melanoma, one of the rarest but...
Obesity and melanoma: a new link
Obesity and melanoma: a new link Melanoma p16INK4A Obesity CDKN2A Adipocytes beta-catenin extracellular vesicle Laurence Niéto – MELASPHINX Team – Métabolisme du céramide dans le mélanome : des mécanismes moléculaires à l’immunothérapie Obesity is a...A new immunotherapy strategy for melanoma patients.
A new immunotherapy strategy for melanoma patients. Anti-TNF Anti-PD-1 Anti-CTLA-4 melanoma Clinical trial Bruno Ségui a Nicolas Meyer – Equipe “MELASPHINX : Sphingolipid metabolism: From basic mechanisms to immunotherapy Melanoma is a skin cancer with a poor...
